AUTHORS
Sameem Abedin, MD, Guru Subramanian Guru Murthy, MD2, Mehdi Hamadani, MD3, Laura C Michaelis, MD4, Karen-Sue Carlson, PhD, MD5, Vijay Reddy, MD, PhD6, Ehab Atallah, MD7
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Actinium Pharmaceuticals, New York, New York, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
ABSTRACT
Introduction
The combination of CLAG-M salvage chemotherapy and the alpha-emitting radioimmunotherapy agent Lintuzumab-Ac225 was evaluated in a Phase I study and has demonstrated encouraging response rates in relapsed/refractory acute myeloid leukemia (RR-AML). A phase II/III study is in development. Both intensive chemotherapy and radiotherapy potentially cause bone marrow suppression or damage, and additionally alpha particles present potential off-target tissue risks, namely long-term liver and kidney toxicities. Characterizing delayed adverse events, particularly prolonged myelosuppression and potential organ toxicities, is essential to assess the safety profile of this intensive regimen, particularly with the goal that responders should transition to curative hematopoietic stem cell transplantation. To this end, we performed a focused evaluation of bone marrow, liver, and kidney toxicities among patients treated with CLAG-M+LintuzumabAc225 for RR-AML.
Methods
A total of 26 patients were enrolled to a Phase I study evaluating the safety and preliminary efficacy of the combination of CLAG-M intensive salvage chemotherapy, with escalating doses of Lintuzumab-Ac225. Lintuzumab-Ac225 was administered as a single dose after CLAG-M at doses of 0.25uCi/kg to 1.0 uCi/kg. One week after therapy, patients also initiated spironolactone for renal protection; this was continued through 1 year or until intolerability to spironolactone. Details for this study and main study results are previously reported (Abedin et al, Leukemia, Apr 2025). In this analysis, we examine subjects who survived at least 3 months post-therapy. To assess marrow toxicity, we identified treatment responders, defined as subjects achieving either a morphologic leukemia free state (MLFS), complete remission (CR) with incomplete count recovery (CRi), or CR, and determined if, post therapy, neutrophils ultimately recovered to >1,000 cells/uL, and platelets recovered to >100,000/uL. Renal toxicity was defined as serum creatinine exceeding the upper limit of normal and 20% above baseline for at least 3 months post-therapy. Liver toxicity was defined as patients meeting criteria for veno-occlusive disorder, or with persistent Grade 1 or greater transaminitis lasting more than 2 weeks.
Results
A total of 18 (69%) of subjects survived at least 3 months post therapy. Assessing bone marrow toxicity, we investigated count recovery in responders. There were 13 responders within this group: 4 (31%) achieved a CR, 8 (62%) achieved a CRi, and 1 (8%) achieved MLFS. Further, among these responders, post-treatment, 6 (46%) patients proceeded to allogeneic HCT, and another 5 (38%) patients who previously underwent allogeneic HCT received a CD34 selected stem cell boost. In total, 12 (92%) patients had full recovery of neutrophils and platelets. Four patients achieved full autologous count recovery within 49 days of salvage therapy. Of the 9 patients achieving CRi or MLFS, 8 patients achieved both neutrophil and platelet recovery after 49 days, and 1 patient achieved neutrophil recovery however relapsed prior to full recovery of platelets.
Organ toxicity was assessed in 18 patients: at 3 months no patients developed chronic kidney injury, there were no cases of VOD, and one patient (6%) patient developed persistent grade 1 transaminitis, which was attributed to graft-vs-host disease (GVHD) and not study therapy. At 12 months, there were 11 survivors: zero had evidence of chronic kidney disease, and 2 (18%) patients had evidence of persistent transaminitis – both cases were attributed to GVHD and not study therapy.
Conclusion
The combination of CLAG-M and Lintuzumab-Ac225 demonstrates an acceptable long-term safety profile in patients with relapsed/refractory AML, without evidence of significant delayed organ toxicity or bone marrow toxicity. Nearly all responders (12/13) exhibited full hematologic recovery. Persistent organ toxicities were rare and primarily attributable to post-transplant GVHD rather than radiopharmaceutical exposure. These findings support the safety of this regimen as a bridge to allogeneic HCT and overall support further clinical evaluation of this intensive combination regimen.
DISCLOSURES
Sameem Abedin, MD: Incyte - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)